secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-178718
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B
---------------------------------------------------------------------------

- Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.
- Enterprise value of $11.75B; combined revenue of $12.4B (Sun Pharma FY24-25 and Organon CY2025).
- Transaction approved by both boards; subject to Organon stockholder vote and regulatory approvals.
- Joseph Morrissey appointed permanent CEO of Organon; Carrie Cox appointed permanent Executive Chair.
- Sun Pharma secured committed financing; pro forma Net Debt/EBITDA of 2.3x expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/0001193125-26-178718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/d38652d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-178718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer